/
Oncology
Myeloid Leukemia
274
Pipeline Programs↗
425
Active Trials↗
158
Companies Involved↗
Myeloid Leukemia is a highly competitive landscape with 274 programs across 158 companies. The most active players are Jiangsu Hansoh Pharmaceutical Co., Ltd., Kartos Therapeutics, Inc., Enliven Therapeutics. 47 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical46
Phase 194
Phase 287
Phase 347
Approved
No programs
Analysis
Modality Breakdown
76%
Small molecule
189 of 248 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 248 classified programs, each share of the total. Modality classified for 95% of 274 pipeline programs.
Analysis
Trial Status
1,306
clinical trials
Completed497 · 38%
Recruiting244 · 19%
Terminated192 · 15%
Unknown status123 · 9%
Active, not recruiting108 · 8%
Not yet recruiting67 · 5%
Other75 · 6%
Clinical Trials
Trial Activity
1306 trials
Page 1 of 88
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)